MyFinsight
Home
Blog
About
Cash, cash
equivalent, restricted...
-$22,586,526
Accounts payable and
accrued expenses
$4,911,963
Stock-based compensation
expense
$3,914,096
Accounts receivable
-$3,253,111
Fair value
adjustment to contingent...
$1,412,000
Amortization expense
$1,165,154
Amortization of right-of-use
asset
$106,716
Accrued interest
$99,083
Depreciation expense
$64,600
Proceeds from issuance of
common stock
$2,500,000
Net cash used in
investing activities
-$15,076,296
Net cash (used in)
provided by operating...
-$6,363,977
Net cash used in
financing activities
-$1,146,253
Canceled cashflow
$14,926,723
Canceled cashflow
$2,500,000
Cash paid in business
combination
$15,018,371
Purchases of property and
equipment and...
$57,925
Net (loss) income
-$17,791,065
Repayments on notes payable
$3,500,000
Inventory
$1,834,615
Gain on
extinguishment of debt
$815,250
Prepaid expenses and
other assets
$364,256
License fees payable
-$295,200
Other current and
long-term liabilities
-$158,802
Income tax payable
-$31,512
Cash paid to third
parties for issuance of...
$146,253
Back
Back
Cash Flow
BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. (BSEM)
source: myfinsight.com